Welcome to our dedicated page for NEWCELX news (Ticker: NLSPW), a resource for investors and traders seeking the latest updates and insights on NEWCELX stock.
The NLSPW news page aggregates announcements and disclosures related to the warrants of NLS Pharmaceutics Ltd., a Swiss-based clinical-stage biopharmaceutical company whose common shares trade on Nasdaq under the symbol NLSP. Because NLSPW is tied to the company’s capital structure, news about these warrants is closely connected to NLS Pharmaceutics’ corporate transactions, financing activities, and strategic developments.
Readers can expect NLSPW-related coverage to reflect key milestones in NLS Pharmaceutics’ evolution, including its proposed and approved merger with Kadimastem Ltd., the planned rebranding and listing of the combined company as NewCelX Ltd. under the ticker NCEL, and the company’s statements that its currently traded warrants will not be listed for trading post-merger. News items often discuss how equity financings, warrant exchanges, and reverse share splits interact with the company’s broader strategic plans.
Beyond capital markets events, NLSPW-linked news will also reference NLS Pharmaceutics’ scientific and clinical updates, since these can influence the context in which the warrants were originally issued. Recent press releases highlight preclinical data for Mazindol in fentanyl use disorder, new findings for the AEX-2 and AEX-41 dual orexin receptor agonists, and expansion of the DOXA platform through collaboration with Aexon Labs. Other announcements describe how the merger with Kadimastem brings together small-molecule CNS programs with cell therapy platforms such as AstroRx® for ALS and IsletRx for diabetes.
By following this page, investors can review how NLSPW fits into the company’s historical financing structure, track corporate actions that may affect the warrants, and read the underlying scientific and strategic news that NLS Pharmaceutics and its merger partner disclose through press releases and SEC-linked communications.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) will participate in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. CEO Alex Zwyer is scheduled for a live interview on September 29 from 1:55 PM to 2:15 PM ET. Attendees can access the interview here, with a replay available on the company website. NLS focuses on developing therapies for rare CNS disorders and is advancing its lead candidate, Quilience, for narcolepsy, which has Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. has initiated a Phase 2 clinical trial for its drug Quilience (mazindol ER) targeting excessive daytime sleepiness and cataplexy in narcolepsy patients. Enrolling around 60 patients across 30 centers in the U.S. and Europe, the trial aims to assess its efficacy over 28 days. Primary endpoints include changes in the Epworth Sleepiness Scale and cataplexy attack frequency. Successful completion could lead to significant advancements in treatment options for narcolepsy, addressing an unmet medical need.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NASDAQ:NLSPW) announces that CEO Alex Zwyer will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Investors can access the presentation online starting September 13 at 1:00 PM CET / 7:00 AM ET. This conference includes six industry tracks, highlighting Healthcare & Biotechnology, and offers networking opportunities. NLS is focused on innovative therapies for central nervous system disorders, with its lead candidate, Quilience, targeting narcolepsy and receiving Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced a Notice of Allowance from the USPTO for patent application No. 16/083,131.
This patent will cover oral formulations with immediate-release and sustained-release layers of mazindol for treating attention deficit disorders (ADD, ADHD), narcolepsy, and excessive daytime sleepiness.
The patent is expected to issue in Q4 2021, expiring no earlier than March 2037. NLS aims to include it in the FDA's Orange Book if market approval is obtained.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced that CEO Alex Zwyer will present at the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. Zwyer's presentation is scheduled for August 12, 2021, at 10:00 AM ET and will be available for live streaming and replay on the company's website. NLS focuses on innovative therapies for rare central nervous system disorders, with its lead product, Quilience, developed for narcolepsy treatment and holding orphan drug designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. has appointed Eric Konofal, M.D., Ph.D., as Chief Scientific Officer. Dr. Konofal, a co-founder with over 30 years of experience in CNS disorders, will focus on advancing the company’s drug pipeline, which includes Quilience® for narcolepsy and five other patented compounds. His leadership is expected to enhance drug development efforts, particularly against disorders like ADHD and Parkinson’s disease. The company recently submitted multiple patent applications, which could strengthen its market position.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced that the FDA has accepted its Investigational New Drug application for Quilience (mazindol ER), the lead candidate for treating narcolepsy. The company plans to launch a Phase 2a clinical trial in August 2021 across the U.S. and Europe, enrolling about 60 patients. The primary objective is to assess changes in excessive daytime sleepiness using the Epworth Sleepiness Scale, with secondary endpoints related to cataplexy attacks. This milestone emphasizes NLS's commitment to developing treatments for central nervous system disorders.
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) announced that CEO Alex Zwyer will present a corporate overview at the First Annual Access to Giving Virtual Investor Conference from July 13-15, 2021. The presentation is scheduled for July 15th at 9:00 am ET, followed by a Q&A session. NLS focuses on innovative therapies for rare central nervous system disorders, with its lead candidate, Quilience®, aimed at treating narcolepsy, receiving Orphan Drug Designations in the U.S. and Europe.